Uncategorized

Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease

Innovent Biologics, Inc. announced that the New Drug Application for IBI311, a recombinant anti-insulin-like growth factor 1 receptor antibody, has been accepted and granted priority review designation by the Center for Drug Evaluation of the China National Drug Administration for the treatment of Thyroid Eye Disease.

Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease Read More »

Scroll to Top